60 likes | 218 Views
ISAR-REACT 3, 1 year outcome. Objective: To assess whether bivalirudin is superior to unfractionated heparin in patients with stable and unstable angina undergoing PCI after pretreatment with clopidogrel . Study: Multicenter, double blind, randomized trial.
E N D
ISAR-REACT 3, 1 year outcome Objective: To assess whether bivalirudinis superior to unfractionated heparin in patients with stable and unstable angina undergoing PCI after pretreatment with clopidogrel. Study: Multicenter, double blind, randomized trial. Population: Patients with stable and unstable angina (normal troponin or CKMB) pretreated with clopidogrel600 mg at least 2 hours before PCI. Endpoint: Composite of death, MI (Q waves, CKMB > 2xULN), ischemia driven TVR at 1 year f-up.
Bivalirudin N=2289 Enrolled N=4570 Unfractionated heparin 140 U/kg N=2281 ISAR-REACT 3, 1 year outcome
ISAR-REACT 3, 1 year outcome Eventrate at 1 year (%) p=0.82 p=0.20 p=0.67 p=0.32 p-=0.18 HR 0.98 (0.86-1.13) 1.15 (0.93-1.43) 1.10 (0.71-1.70)1.13 (0.89-1.14) 0.89 (0.75-1.06)
ISAR-REACT 3, 1 year outcome Conclusion: Bivalirudin and unfractionated heparin during PCI provide comparable outcomes at 1 year in biomarker negative patients undergoing PCI after pre-treatment with 600 mg of clopidogrel. Schultz et al. Eur Heart J 2010;31:582-7